Mounjaro®
Starting from £179.99/mo
Start journey Learn moreA single 5mg dose of semaglutide stays active in the body for roughly one week, which is why it is taken once weekly. That seven-day half-life is built into the licensed schedule from the outset: 5mg is one step on the titration ladder, not a long-term stopping point. These are prescription-only medicines; a clinician assesses whether the schedule suits you before any dose is dispensed.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
People often assume that because a dose is higher, it must stay in the body for longer. With semaglutide, that is not how it works. The molecule's half-life (roughly seven days) is a fixed pharmacological property, not something that scales up with the milligram number. Whether someone is taking 0.5mg or 5mg, one injection is designed to cover one week. What changes with the dose is the intensity of the effect, not how long the medicine physically remains active.
This matters because it reshapes the right questions to ask. If you notice that appetite suppression feels weaker by day six or seven, that is the natural trough in the dosing cycle, it happens at every dose level and does not mean 5mg has worn off faster than a smaller dose would. The duration of a single semaglutide dose is explored in more detail on a dedicated page, but the short answer is consistent: one week, regardless of strength.
A quick habit worth building: once you settle into a weekly routine, jot your injection day on your phone calendar with a one-day-early reminder. It takes under a minute to set up and removes any ambiguity about whether you are on day six or day eight.
Semaglutide for weight management in the UK is licensed under the brand name Wegovy, made by Novo Nordisk. The titration path runs 0.25mg, 0.5mg, 1.0mg, 1.7mg and 2.4mg (with 7.2mg now approved by the MHRA as a higher maintenance option). 5mg does not appear in the standard Wegovy schedule, it is a dose associated with the Ozempic range, which is licensed for type 2 diabetes, not weight management. If you have seen 5mg referenced in the context of weight loss, it may relate to compounded or unlicensed products, which carry serious safety risks.
The full Wegovy dose schedule explains each step in practical terms. Briefly: earlier doses like 0.25mg and 0.5mg are tolerability phases, giving the body time to adjust before the therapeutic doses take over. The prescriber decides when each increase happens, based on tolerability and response. Rushing that ladder is not clinically appropriate, and no responsible service should offer it. The NHS medicines information for semaglutide, available at nhs.uk/medicines/semaglutide, sets out the schedule clearly for patients.
If you are wondering how duration changes at the highest licensed dose, the 10mg semaglutide duration page addresses that directly, the seven-day principle still applies.
After a subcutaneous injection, semaglutide is absorbed slowly from the tissue under the skin, reaches peak plasma concentration in about one to three days, then gradually declines. The GLP-1 receptor activity it produces (reducing appetite, slowing gastric emptying, influencing blood-sugar regulation) mirrors that concentration curve. Peak effect tends to land in the first few days; by day seven the level is still sufficient to maintain the therapeutic effect, which is why the once-weekly schedule works. After stopping completely, meaningful levels persist for several weeks, something explored in depth on the page about semaglutide after the last dose.
None of this should be used to self-adjust timing or dose. NICE's appraisal of semaglutide for weight management, TA875, reinforces that treatment decisions (including any changes to the schedule) are made within a clinical framework, not independently. If your injection day needs to shift by a day or two for travel or other practical reasons, the Patient Information Leaflet explains the permitted flexibility, and your prescriber can confirm what applies to you.
Wegovy is a prescription-only medicine. In the UK, the only legal route to it is a prescription issued by a qualified prescriber following a clinical assessment. There is no version of the process that skips that step legitimately. If you are weighing up the private route, the Wegovy pricing page sets out what a genuine private prescription typically costs and what those costs should always include: consultation, prescription, and clinical oversight.
Understanding what the recommended dose of semaglutide actually is can help you put any specific milligram figure in context, whether you encountered it online, in the press, or from a friend's experience. Treatment is not one-size-fits-all. A prescriber reviews the whole picture. If you would like to find out whether Wegovy is clinically appropriate for you, you can start a free consultation with our GPhC-registered prescribers today, no commitment, same-day review if you apply before noon on a working day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.